156 results
Page 5 of 8
8-K
EX-99.1
g0mo7xj
24 Oct 12
Bristol-Myers Squibb Reports Third Quarter 2012 Financial Results
12:00am
SC TO-T/A
EX-99
keurb3n9
19 Jan 12
Third party tender offer statement (amended)
12:00am
SC TO-T
EX-99
i8i2 ga8clk
13 Jan 12
Third party tender offer statement
12:00am
SC TO-T
EX-99
4uy9iwh7 i711h59d
13 Jan 12
Third party tender offer statement
12:00am
8-K
EX-99.1
widsm1y4
9 Jan 12
Bristol-Myers Squibb to Acquire Inhibitex
12:00am
8-K
EX-99.1
45i53gvib1 js6zs
27 Oct 11
Bristol-Myers Squibb Delivers Strong Third Quarter with Important Clinical Data, Solid Operating Results and Continued Focus on Business Development
12:00am
8-K
EX-99.1
0l7rfk4bkrvncude
28 Jul 11
Important Clinical Data and Strong Financial Results
12:00am
8-K
EX-99.1
kg7 5itt5na0ne
27 Jan 11
Receives U.S. Regulatory Approval for KOMBIGLYZE™ XR, and First-Line Indication for SPRYCEL® in Fourth Quarter
12:00am
8-K
EX-99.1
r6pwek
26 Oct 10
Robust Clinical Data and the Strategic Acquisition of ZymoGenetics
12:00am
SC TO-T/A
EX-99
jf41978bhsd
29 Sep 10
Third party tender offer statement (amended)
12:00am
SC TO-T/A
EX-99
17a9gafjj
13 Sep 10
Third party tender offer statement (amended)
12:00am
8-K
EX-99.1
06n8z8p xyvnxxufklb
22 Jul 10
Bristol-Myers Squibb Second Quarter Featured Robust Clinical Data
12:00am